Pharmacogenetics of Clinical Response to Risperione

• Cáceres MC , Peñas-LledóEM, de la Rubia A, LLerena A. Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. Eur. J. Clin. Pharmacol.64(1) , 73–76 (2008).
   PubMed Web of Science ®Google Scholar
• Heykants J , HuangML, MannensG et al. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 55(Suppl.) , 13–17 (1994)
   PubMed Web of Science ®Google Scholar
• Huang M -L, Van Peer A, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther.54(3) , 257–268 (1993).
   PubMed Web of Science ®Google Scholar
• Cohen LJ . Risperidone. Pharmacotherapy14(3) , 253–265 (1994).
   PubMed Web of Science ®Google Scholar
• Locatelli I , KastelicM, KoprivsekJ et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur. J. Pharm. Sci. 41(2) , 289–298 (2010).
   PubMed Web of Science ®Google Scholar
• Jovanovic N , BozinaN, LovricM, MedvedV, JakovljevicM, PelesAM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol.66(11) , 1109–1117 (2010).
   PubMed Web of Science ®Google Scholar
• Xiang Q , ZhaoX, ZhouY, DuanJL, CuiYM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J. Clin. Pharmacol.50(6) , 659–666 (2010).
   PubMed Web of Science ®Google Scholar
• Riedel M , SchwarzMJ, StrassnigM et al. Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 255(4) , 261–268 (2005).
   PubMed Web of Science ®Google Scholar
• Kakihara S , YoshimuraR, ShinkaiK et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int. Clin. Psychopharmacol. 20(2) , 71–78 (2005).
   PubMed Web of Science ®Google Scholar
• Spina E , AvenosoA, FacciolàG et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther. Drug Monit. 23(3) , 223–227 (2001).
   PubMed Web of Science ®Google Scholar
• Darby JK , PastaDJ, WilsonMG, HerbertJ. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin. Drug Investig.28(9) , 553–564 (2008).
   PubMed Web of Science ®Google Scholar
• Furukori N . Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi30(2) , 65–69 (2010).
   PubMedGoogle Scholar
• Fleeman N , DundarY, DicksonR et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 11(1) , 1–14 (2011).
   PubMed Web of Science ®Google Scholar
• Scordo MG , SpinaE, FacciolàG, AvenosoA, JohanssonI, DahlML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl.)147(3) , 300–305 (1999).
   PubMed Web of Science ®Google Scholar
• Berecz R , LLerenaA, de la Rubia A et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry35(6) , 231–234 (2002).
   PubMed Web of Science ®Google Scholar
• de Leon J , ArmstrongSC, CozzaKL. The dosing of atypical antipsychotics. Psychosomatics46(3) , 262–273 (2005).
   PubMed Web of Science ®Google Scholar
• de Leon J , SandsonNB, CozzaKL. A preliminary attempt to personalize risperidone dosing using drug–drug interactions and genetics: part II. Psychosomatics49(4) , 347–361 (2008).
   PubMed Web of Science ®Google Scholar
• Bork J , RogersT, WedlundP, de Leon J. A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J. Clin. Psychiatry60(7) , 469–476 (1999).
   PubMed Web of Science ®Google Scholar
• Jover F , CuadradoJM, AndreuL, MerinoJ. Reversible coma caused by risperidone-ritonavir interaction. Clin. Neuropharmacol.25(5) , 251–253 (2002).
   PubMed Web of Science ®Google Scholar
• Kohnke MD , GrieseEU, StosserD, GaertnerI, BrathG. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry35(3) , 116–118 (2002).
   PubMed Web of Science ®Google Scholar
• Spina E , AvenosoA, ScordoMG et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol. 22(4) , 419–423 (2002).
   PubMed Web of Science ®Google Scholar
• Yagihashi T , MizunoM, ChinoB et al. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol. 24(4) , 301–308 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki Y , FukuiN, TsuneyamaN et al. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. Hum. Psychopharmacol. 27(1) , 43–46 (2012).
   PubMed Web of Science ®Google Scholar
• Hendset M , MoldenE, RefsumH, HermannM. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J. Clin. Psychopharmacol.29(6) , 537–541 (2009).
   PubMed Web of Science ®Google Scholar
• de Leon J , SusceMT, PanRM, FairchildM, KochW, WedlundPJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry66(1) , 15–27 (2005).
   PubMed Web of Science ®Google Scholar
• Calarge CA , Miller del D. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J. Child. Adolesc. Psychopharmacol.21(2) , 163–169 (2011).
   PubMed Web of Science ®Google Scholar
• Guzey C , AamoT, SpigsetO. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultra-rapid metabolizer. J. Clin. Psychiatry61(8) , 600–601 (2000).
   PubMedGoogle Scholar
• Albrecht A , MorenaPG, BaumannP, EapCB. High dose of depot risperidone in a nonresponder schizophrenic patient. J. Clin. Psychopharmacol.24(6) , 673–674 (2004).
   PubMed Web of Science ®Google Scholar
• LLerena A , KiivetRA. Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use. Br. J. Clin. Pharmacol.37(6) , 531–532 (1994).
   PubMed Web of Science ®Google Scholar
• Mannheimer B , von Bahr C, Pettersson H, Eliasson E. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther. Drug. Monit.30(5) , 565–569 (2008).
   PubMed Web of Science ®Google Scholar
• Berecz R , DoradoP, De La Rubia A, Cáceres MC, Degrell I, LLerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug. Targets.5(6) , 573–579 (2004).
   PubMed Web of Science ®Google Scholar
• Prior TI , BakerGB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci.28(2) , 99–112 (2003).
   PubMed Web of Science ®Google Scholar
• Benazzi F . Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry32(1) , 41 (1999).
   PubMed Web of Science ®Google Scholar
• Raaska K , RaitasuoV, NeuvonenPJ. Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur. J. Clin. Pharmacol.58(9) , 587–591 (2002).
   PubMed Web of Science ®Google Scholar
• de Wildt SN , KearnsGL, LeederJS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet.37(6) , 485–505 (1999).
   PubMed Web of Science ®Google Scholar
• Mahatthanatrakul W , NontaputT, RidtitidW, WongnawaM, SunbhanichM. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J. Clin. Pharm. Ther.32(2) , 161–167 (2007).
   PubMed Web of Science ®Google Scholar
• Spina E , AvenosoA, FacciolaG et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug. Monit. 22(4) , 481–485 (2000).
   PubMed Web of Science ®Google Scholar
• Jung SM , KimKA, ChoHK et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin. Pharmacol. Ther. 78(5) , 520–528 (2005).
   PubMed Web of Science ®Google Scholar
• Mahatthanatrakul W , SriwiriyajanS, RidtitidW et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J.Clin. Pharm. Ther. 37(2) , 221–225 (2012).
   PubMed Web of Science ®Google Scholar
• Boulton DW , DeVaneCL, ListonHL, MarkowitzJS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci.71(2) , 163–169 (2002).
   PubMed Web of Science ®Google Scholar
• Marzolini C , PausE, BuclinT, KimRB. Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther.75(1) , 13–33 (2004).
   PubMed Web of Science ®Google Scholar
• de León J , SusceMT, PanRM, WedlundPJ, OrregoML, DiazFJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry40(3) , 93–102 (2007).
   PubMed Web of Science ®Google Scholar
• Yoo HD , LeeSN, KangHA, ChoHY, LeeIK, LeeYB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br. J. Pharmacol.164(2b) , 433–443 (2011).
   PubMed Web of Science ®Google Scholar
• Mas S , GassòP, AlvarezS, ParelladaE, BernardoM, LafuenteA. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J.12(3) , 255–259 (2012).
   PubMed Web of Science ®Google Scholar
• Izzo AA , ErnstE. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs69(13) , 1777–1798 (2009).
   PubMed Web of Science ®Google Scholar
• Xuan J , ZhaoX, HeG et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 33(2) , 305–311 (2008).
   PubMed Web of Science ®Google Scholar
• Remington G , KapurS. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J. Clin. Psychiatry60(Suppl. 10) , 15–19 (1999).
   PubMedGoogle Scholar
• Regenthal R , KunstlerU, HesseS, SabriO, PreissR. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int. J. Clin. Pharmacol. Ther.43(8) , 370–378 (2005).
   PubMed Web of Science ®Google Scholar
• Tauscher J , KapurS. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs15(9) , 671–678 (2001).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A , LaruelleM, AghajanianGK, CharneyD, CristalJ. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatr. Clin. Neuroscience9(1) , 1–17 (1997).
   PubMed Web of Science ®Google Scholar
• Vázquez-Bourgon J , ArranzMJ, MataI et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res. 175(3) , 189–194 (2010).
   PubMed Web of Science ®Google Scholar
• Liperoti R , OnderG, LandiF et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J. Clin. Psychiatry 70(10) , 1340–1347 (2009).
   PubMed Web of Science ®Google Scholar
• Huybrechts KF , SchneeweissS, GerhardT et al. Comparative safety of antipsychotic medications in nursing home residents. J. Am. Geriatr. Soc. 60(3) , 420–429 (2012).
   PubMed Web of Science ®Google Scholar
• Kales HC , KimHM, ZivinK et al. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 169(1) , 71–79 (2012).
   PubMed Web of Science ®Google Scholar
• Maher A , MaglioneM, BagleyS et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12) , 1359–1369 (2011).
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M , ClarkDW. Nose bleeds associated with use of risperidone. BMJ328(7453) , 1416 (2004).
   PubMedGoogle Scholar
• Morrato EH , NewcomerJW, KamatS, BaserO, HarnettJ, CuffelB. Metabolic screening after the American Diabetes Association‘s consensus statement on antipsychotic drugs and diabetes. Diabetes Care32(6) , 1037–1042 (2009).
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C , KomossaK, SchwarzS et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 123(2–3) , 225–233 (2010).
   PubMed Web of Science ®Google Scholar
• Lane HY , LiuYC, HuangCL et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 26(2) , 128–134 (2006).
   PubMed Web of Science ®Google Scholar
• Lett TA , WallaceTJ, ChowdhuryNI, TiwariK, KennedyJL, MüllerDJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry17(3) , 242–246 (2012).
   PubMed Web of Science ®Google Scholar
• Lencz T , RobinsonDG, NapolitanoB et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet. Genomics20(9) , 569–572 (2010).
   PubMed Web of Science ®Google Scholar
• Adkins DE , AbergK, McClayJL et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 16(3) , 321–332 (2011).
   PubMed Web of Science ®Google Scholar
• Smith RC , SegmanRH, Golcer-DubnerT, PavlovV, LererB. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J.8(3) , 228–236 (2008).
   PubMed Web of Science ®Google Scholar
• Reynolds GP , ZhangZ, ZhangX. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am. J. Psychiatry160(4) , 677–679 (2003).
   PubMed Web of Science ®Google Scholar
• Mulder H , FrankeB, van der-Beek van der AA et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J.7(5) , 318–324 (2007).
   PubMed Web of Science ®Google Scholar
• Mulder H , CohenD, SchefferH et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol.29(1) , 16–20 (2009).
   PubMed Web of Science ®Google Scholar
• Bai YM , ChenTT, LiouYJ, HongCJ, TsaiSJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr. Res.125(2–3) , 179–186 (2011).
   PubMed Web of Science ®Google Scholar
• Correia CT , AlmeidaJP, SantosPE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 10(5) , 418–430 (2010).
   PubMed Web of Science ®Google Scholar
• Kato D , KawanishiC, KishidaI et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur. J. Clin. Pharmacol. 63(11) , 991–996 (2007).
   PubMed Web of Science ®Google Scholar
• Ochi S , KawasoeK, AbeM et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen. Hosp. Psychiatry 33(6) , 1–2 (2011).
   PubMedGoogle Scholar
• Kuzman MR , MedvedV, BozinaN, GrubišinJ, JovanovicN, SerticJ. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J.11(1) , 35–44 (2011).
   PubMed Web of Science ®Google Scholar
• Mulder H , CohenD, SchefferH et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol.29(1) , 16–20 (2009).
   PubMed Web of Science ®Google Scholar
• Gassó P , MasS, BernardoM, AlvarezS, ParelladaE, LafuenteA. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J.9(6) , 404–410 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene. multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7) , 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Ito S , IeiriI, TanabeM, SuzukiA, HiguchiS, OtsuboK. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics11(2) , 175–184 (2001).
   PubMedGoogle Scholar
• Greenbaum L , StrousRD, KanyasK et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet. Genomics 17(7) , 519–528 (2007).
   PubMed Web of Science ®Google Scholar
• Szarfman A , TonningJM, LevineJG, DoraiswamyPM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy26(6) , 748–758 (2006).
   PubMed Web of Science ®Google Scholar
• Shinkai T , De Luca V, Utsunomiya K et al. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med.10(4) , 362–367 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L , FangC, ZhangA et al. The 1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 22(8) , 904–909 (2008).
   PubMed Web of Science ®Google Scholar
• Schotte A , JanssenPF, GommerenW et al. Risperidone compared with new and reference antipsychotic drugs: in-vitro and in-vivo receptor binding. Psychopharmacology (Berl.) 124(1–2) , 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Richelson E , SouderT. Binding of antipsychotic drugs to human brain receptors: focus on newer-generation compounds. Life Sci.68(1) , 29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Arranz MJ , RiveraM, MunroJC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs25(11) , 933–969 (2011).
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N , TsuchimineS, SaitoM et al. Comparing the influence of dopamine D2 polymorphisms and plasma drug concentrations on the clinical response to risperidone. J. Clin. Psychopharmacol. 31(5) , 633–637 (2011).
   PubMed Web of Science ®Google Scholar
• Xing Q , QianX, LiH et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int. J. Neuropsychopharmacol. 10(5) , 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Lencz T , RobinsonDG, XuK et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry163(3) , 529–531 (2006).
   PubMed Web of Science ®Google Scholar
• Ikeda M , YamanouchiY, KinoshitaY et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 9(10) , 1437–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Dolzan V , PlesnicarBK, SerrettiA et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 44B(6) , 809–815 (2007).
   Google Scholar
• Lane HY , LeeCC, ChangYC et al. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int. J. Neuropsychopharmacol. 7(4) , 461–470 (2004).
   PubMed Web of Science ®Google Scholar
• Yamanouchi Y , IwataN, SuzukiT, KitajimaT, IkedaM, OzakiN. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J.3(6) , 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki M , HurdYL, SokoloffP, SchwartzJC, SedvallG. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res.779(1–2) , 58–74 (1998).
   PubMed Web of Science ®Google Scholar
• Schwartz JC , DiazJ, PilonC, SokoloffP. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res. Rev.31(2–3) , 277–287 (2000).
   PubMed Web of Science ®Google Scholar
• Bressan RA , ErlandssonK, JonesHM, MulliganRS, EllPJ, PilowskyLS. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J. Clin. Psychopharmacol.23(1) , 5–14 (2003).
   PubMed Web of Science ®Google Scholar
• Stone JM , BressanRA, ErlandssonK et al. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology (Berl.) 180(4) , 664–669 (2005).
   PubMed Web of Science ®Google Scholar
• Sokoloff P , AndrieuxM, BesanconR et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 225(4) , 331–337 (1992).
   PubMed Web of Science ®Google Scholar
• Schmauss C , HaroutunianV, DavisKL, DavidsonM. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl Acad. Sci. USA90(19) , 8942–8946 (1993).
   PubMed Web of Science ®Google Scholar
• Gurevich EV , BordelonY, ShapiroRM, ArnoldSE, GurRE, JoyceJN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry54(3) , 225–232 (1997).
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A , MamoD, ShammiCM et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO. Arch. Gen. Psychiatry 66(6) , 606–615 (2009).
   PubMed Web of Science ®Google Scholar
• Mizrahi R , AgidO, BorlidoC et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr. Res. 131(1–3) , 63–68 (2011).
   PubMed Web of Science ®Google Scholar
• Witkin J , GasiorM, AcriJ et al. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. Eur. J. Pharmacol. 347(2–3) , R1–R3 (1998).
   PubMed Web of Science ®Google Scholar
• Fink-Jensen A . Novel pharmacological approaches to the treatment of schizophrenia. Dan. Med. Bull.47 , 151–167 (2000).
   PubMedGoogle Scholar
• Kim B , ChoiEY, KimCY, SongK, JooYH. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum. Psychopharmacol.23(1) , 61–67 (2008).
   PubMed Web of Science ®Google Scholar
• Lane HY , HsuSK, LiuYC, ChangYC, HuangCH, ChangWH. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol.25(1) , 6–11 (2005).
   PubMed Web of Science ®Google Scholar
• Vehof J , BurgerH, WilffertB et al. Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes. Eur. Neuropsychopharmacol. 22(9) , 625–631 (2012).
   PubMed Web of Science ®Google Scholar
• Szekeres G , KériS, JuhászA et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 124B(1) , 1–5 (2004).
   PubMed Web of Science ®Google Scholar
• Reynolds GP , YaoZ, ZhangX, SunJ, ZhangZ. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur. Neuropsychopharmacol.15(2) , 143–151 (2005).
   PubMed Web of Science ®Google Scholar
• Le François B , CzesakM, SteublD, AlbertPR. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology55(6) , 977–985 (2008).
   PubMed Web of Science ®Google Scholar
• Ichikawa J , IshiiH, BonaccorsoS, FowlerWL, O‘LaughlinIA, MeltzerHY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem.76(5) , 1521–1531 (2001).
   PubMed Web of Science ®Google Scholar
• Diaz-Mataix L , ScorzaMC, BortolozziA, TothM, CeladaP, ArtigasF. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci.25(47) , 10831–10843 (2005).
   PubMed Web of Science ®Google Scholar
• Mössner R , SchuhmacherA, KühnKU et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet. Genomics 19(1) , 91–94 (2009).
   PubMed Web of Science ®Google Scholar
• Meltzer HY , LiZ, KanedaY, IchikawaJ. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry27(7) , 1159–1172 (2003).
   PubMed Web of Science ®Google Scholar
• Lane HY , ChangYC, ChiuCC, ChenML, HsiehMH, ChangWH. Association of risperidone treatment response with a polymorphism in the 5HT (2A) receptor gene. Am. J. Psychiatry159(9) , 1593–1595 (2002).
   PubMed Web of Science ®Google Scholar
• Angelucci F , BernardiniS, GravinaP et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer‘s disease: a 3-year follow-up longitudinal study. J. Alzheimers. Dis. 17(1) , 203–211 (2009).
   PubMed Web of Science ®Google Scholar
• Bonhaus DW , WeinhardtKK, TaylorM et al. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36(4–5) , 621–629 (1997).
   PubMed Web of Science ®Google Scholar
• Tecott LH , SunLM, AkanaSF et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374(6522) , 542–546 (1995).
   PubMed Web of Science ®Google Scholar
• Smith SR , WeissmanNJ, AndersonCM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363(3) , 245–256 (2010).
   PubMed Web of Science ®Google Scholar
• Lane HY , LinCC, HuangCH, ChangYC, HsuSK, ChangWH. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res.67(1) , 63–70 (2004).
   PubMed Web of Science ®Google Scholar
• Pouzet B , DidriksenM, ArntJ. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav.71(4) , 635–643 (2002).
   PubMed Web of Science ®Google Scholar
• Ruat M , TraiffortE, LeursR, Tardivel-LacombeJ, DiazJ, ArrangJM. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc. Natl Acad. Sci. USA90(18) , 8547–8551 (1993).
   PubMed Web of Science ®Google Scholar
• Wei Z , WangL, XuanJ et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(3) , 547–551 (2009).
   PubMed Web of Science ®Google Scholar
• Veenstra-Vanderweele J , AndersonGM, CookEH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur. J. Pharmacol.410(2–3) , 165–181 (2000).
   PubMed Web of Science ®Google Scholar
• Kraft JB , SlagerSL, McGrathPJ, HamiltonSP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry58(5) , 374–381 (2005).
   PubMed Web of Science ®Google Scholar
• Mata I , ArranzMJ, PatiñoA et al. Serotonergic polymorphisms and psychotic disorders in populations from north Spain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126B(1) , 88–94 (2004).
   PubMed Web of Science ®Google Scholar
• Arranz MJ , de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12(8) , 707–747 (2007).
   PubMed Web of Science ®Google Scholar
• Dolzan V , SerrettiA, MandelliL, KoprivsekJ, KastelicM, PlesnicarBK. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog. Neuropsychopharmacol. Biol. Psychiatry32(6) , 1562–1566 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L , YuL, HeG et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci. Lett. 414(1) , 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Korte M , CarrolP, WolfE, BremG, ThoenenH, BonhoefferT. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl Acad. Sci. USA92(19) , 8856–8860 (1995).
   PubMed Web of Science ®Google Scholar
• Figurov A , Pozzo-MillerLD, OlafssonP, WangT, LuB. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature381(6584) , 706–709 (1996).
   PubMed Web of Science ®Google Scholar
• Shoval G , WeizmanA. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol.15(3) , 319–329 (2005).
   PubMed Web of Science ®Google Scholar
• Guillin O , DiazJ, CarrollP, GriffonN, SchwartzJC, SokoloffP. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature411(6833) , 86–89 (2001).
   PubMed Web of Science ®Google Scholar
• Pröschel M , SaundersA, RosesAD, MüllerCR. Dinucleotide repeat polymorphism at the human gene for brain-derived neurotrophic factor (BDNF). Hum. Mol. Genet.1(5) , 353 (1992).
   PubMedGoogle Scholar
• Cargill M , AltshulerD, IrelandJ et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22(3) , 231–238 (1999).
   PubMed Web of Science ®Google Scholar
• Kunugi H , UekiA, OtsukaM et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer‘s disease. Mol. Psychiatry 6(1) , 83–86 (2001).
   PubMed Web of Science ®Google Scholar
• Ribasés M , GratacósM, ArmengolL et al. Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Mol. Psychiatry 8(8) , 745–751 (2003).
   PubMed Web of Science ®Google Scholar
• Krebs MO , GuillinO, BourdellMC et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry 5(5) , 558–562 (2000).
   PubMed Web of Science ®Google Scholar
• Anttila S , IlliA, KampmanO, MattilaKM, LehtimäkiT, LeinonenE. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J. Neural. Transm.112(7) , 885–890 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang XY , TanYL, ZhouDF et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J. Psychiatr. Res. 41(12) , 997–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Egan MF , KojimaM, CallicottJH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2) , 257–269 (2003).
   PubMed Web of Science ®Google Scholar
• Chen CC , HuangTL. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res.189(3) , 327–330 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshimura R , HoriH, SugitaA et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(5) , 1072–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Szczepankiewicz A , SkibinskaM, CzerskiPM et al. No association of the brain-derived neurotrophic factor (BDNF) gene C-270T polymorphism with schizophrenia. Schizophr. Res. 76(2–3) , 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Xu M , LiS, XingQ et al. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur. J. Hum. Genet. 18(6) , 707–712 (2010).
   PubMed Web of Science ®Google Scholar
• Egan MF , GoldbergTE, KolachanaBS et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98(12) , 6917–6922 (2001).
   PubMed Web of Science ®Google Scholar
• Kang CY , XuXF, ShiZY, YangJZ, LiuH, XuHH. Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Psychiatry Res.176(1) , 94–95 (2010).
   PubMed Web of Science ®Google Scholar
• Lane HY , LiuYC, HuangCL et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J. Clin. Psychopharmacol.28(1) , 64–68 (2008).
   PubMed Web of Science ®Google Scholar
• Xing Q , GaoR, LiH et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7) , 987–993 (2006).
   PubMed Web of Science ®Google Scholar
• Kastelic M , KoprivšekJ, PlesnicarBK et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry34(2) , 387–392 (2010).
   PubMed Web of Science ®Google Scholar
• Méary A , BrousseG, JamainS et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(4) , 491–494 (2008).
   PubMed Web of Science ®Google Scholar
• Wei Z , WangL, ZhangM et al. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J. Psychopharmacol. 26(6) , 813–818 (2012).
   PubMed Web of Science ®Google Scholar
• Ikeda M , TomitaY, MouriA et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case–control association approaches. Biol. Psychiatry 67(3) , 263–269 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao QZ , LiuBC, ZhangJ et al. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr. Genet. 22(6) , 298–299 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• EMA. Risperdal (2008). www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Risperdal/human_referral_000022.jsp (Accessed 30August2012)
   Google Scholar
• US FDA. Risperdal (2012). www.accessdata.fda.gov/drugsatfda_docs/label/2012/020272s065,020588s053,021444s041lbl.pdf (Accessed 30August2012)
   Google Scholar